

Application No.: 09/682,562  
Attorney Docket No.: TNX 00-08  
Customer No.: 26839

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method of stimulating antibody dependent cellular cytotoxicity ("ADCC") to enhance the elimination of IgE-bearing B cells comprising:
  - a. administering to a mammal an anti-IgE antibody which binds to membrane bound IgE, but does not induce histamine release; and
  - b. administering an [[ISO]] immune stimulatory oligonucleotide ("ISO") to the mammal.
2. (Currently Amended) The method of claim 1 wherein the ISO is a CpG containing oligonucleotide, or a modified CpG-containing oligonucleotide with an electron-withdrawing group at least at position C-5 of the cytosine in the CpG sequence.
3. (Original) The method of claim 1 wherein the antibody has a human IgG1 or IgG3 Fc portion, or a mouse IgG2a Fc region.
4. (Original) The method of claim 2 wherein the anti-IgE antibody is Hu-901, E25, E26 or E27.
5. (Currently Amended) The method of any of claims 1 to 4, further including administering an allergen to the subject mammal.
6. (Original) The method of claim 5 wherein the allergen is conjugated to the CpG-containing oligonucleotide.
7. (Original) The method of claim 5 wherein the mammal is a human being.
8. (Currently Amended) The method of claims claim 5 wherein the CpG-containing oligonucleotide has the formula: NDCGHN (SEQ ID NO 5), wherein N is any nucleotide, D is any nucleotide other than cytosine and H is any nucleotide other than guanine.
9. (Original) The method of claim 5 wherein CpG-containing oligonucleotide has one of the following sequences: AACGTTCC (SEQ ID NO 1), AACGTCG (SEQ ID NO 2), GACGTTCC (SEQ ID NO 3) or GACGTTCG (SEQ ID NO 4).